SCHEMBL1665671

SCHEMBL1665671

O=c1c2ccc(O)cc2nc(Cc2ccco2)n1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
ESR1 P03372 2/20 0.46
TSHR P16473 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PDE10A Q9Y233 3/20 0.44
TP53 P04637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1664336 0.80 ESR1 (0.60) ALDH1A1SMN1; SMN2ESR1TSHRPDE10A
SCHEMBL1666112 0.78 PDE10A (0.53) ALDH1A1SMN1; SMN2ESR1TSHRPDE10A
SCHEMBL1663442 0.77 ESR1 (0.50) ALDH1A1SMN1; SMN2ESR1PDE10ALMNA
SCHEMBL1664551 0.77 PDE10A (0.50) ALDH1A1SMN1; SMN2ESR1PDE10ALMNA
SCHEMBL1663101 0.77 ALDH1A1 (0.45) ALDH1A1ESR1TSHRPDE10AKDM4E
SCHEMBL1663630 0.74 ESR1 (0.57) ALDH1A1SMN1; SMN2ESR1TSHRCYP1A2
SCHEMBL1664004 0.73 ESR1 (0.84) ALDH1A1SMN1; SMN2ESR1KDM4EGAA
SCHEMBL12798644 0.71 HTR7 (0.50) ALDH1A1PDE10ANPSR1HTR7
SCHEMBL1663648 0.71 ESR1 (0.53) ALDH1A1SMN1; SMN2ESR1TSHRCYP1A2
SCHEMBL1663398 0.71 TRPV1 (0.72) ALDH1A1SMN1; SMN2ESR1TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 ALDH1A1 2499/4885SMN1; SMN2 4016/4885ESR1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.